The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications. - Wikidata - wikimedia - TriplyDB

The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.

The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.

http://www.wikidata.org/entity/Q38269155

about

Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer DNA methylation as a dynamic regulator of development and disease processes: spotlight on the prostate DNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer Cells Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality.Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients.A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.Elevated expression of PTCD3 correlates with tumor progression and predicts poor prognosis in patients with prostate cancer

P2860

Q30764223-394C3A9D-4576-43DD-8E82-541B719C84A0 Q35847749-282FAC2F-5192-434C-B458-BC47700F8B97 Q36190050-B4BD784F-1863-4EF8-BEC3-CFD2EBA69CBA Q37629548-1C8EDBEB-4593-4423-B7C4-99A14C7EC9F6 Q40454546-BF875D69-C382-479C-B087-428E9A265E5E Q42256326-BB1B6BA6-793E-416F-90C5-D14B66F22091 Q42651317-5DF3858D-0210-43AE-B76E-0A8B3752CD23 Q43169980-FD4076FE-C687-43FF-9B9C-D476ED3A6A29 Q55517990-E7E691A7-ABB9-440A-BEBF-DF4831196B2F Q58733629-627DA5B8-467C-49AD-98E4-6A0A4CB9762C

P2860

The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.

http://www.wikidata.org/entity/Q38269155

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

The epigenetics of prostate ca ...... date on clinical applications.

@en

type

label

The epigenetics of prostate ca ...... date on clinical applications.

@en

prefLabel

The epigenetics of prostate ca ...... date on clinical applications.

@en

P1433

Q38269155-2C583231-2951-4BF5-86A4-821BF96B3F42

P1476

Q38269155-F217E56A-88DA-4066-BADB-6443DDC24DD9

P2093

Q38269155-044DA993-2CD4-43FE-8E6B-8669F6053D00

Q38269155-0B94D6F7-3246-4761-837A-A3D03253C61F

Q38269155-91FE4368-9F67-48EE-BA9C-AE423C61D22E

P2860

Q38269155-0E170D2F-4B46-4742-94E8-B8B12311E4B9

Q38269155-2427FDBA-6637-43BC-981F-0EC91E036CE7

Q38269155-27BFF581-D2E6-4B8C-9F4D-7A68F273CF75

Q38269155-28B8734F-C570-445B-BB4B-0664B2406F8A

Q38269155-2F41EFC1-19F2-4F0E-9B2C-82BFAE3D324C

Q38269155-34E2B356-7D07-469C-ABBC-063B9036F7FB

Q38269155-37CA5C38-4509-49C2-9857-2FA8479C5A1E

Q38269155-4362DF23-5159-4C71-B7CC-42D336D294BB

Q38269155-437C13B8-DB7E-46E9-A1C6-1658B5F4B0F5

Q38269155-46E0A552-585F-4BE9-B729-A924A0761814

P304

Q38269155-3D1F7DB9-1AA5-4C5A-AAF4-C1C4DD8D6AC2

P31

Q38269155-FA6ED1EF-4B6B-4143-8790-FA046C37D271

P356

Q38269155-667F272C-8153-46A8-9609-97607ACBE397

P433

Q38269155-66D32849-8581-4764-A0B1-537DA5B98C11

P478

Q38269155-31B98827-5EF6-4EF1-883A-5AEC81AD341C

P577

Q38269155-115FD676-6F8F-451C-80BE-E693FDF84451

P698

Q38269155-0292B160-1D1F-4B37-9686-D4FDFD9857A2

P921

Q38269155-14781228-a07f-4e0f-ba65-2cbf03166082

P932

Q38269155-D70BE756-762C-46F2-A649-9C4F60C4DBDA

P356

MOU.0000000000000132

P1433

Current Opinion in Urology

P1476

The epigenetics of prostate ca ...... date on clinical applications.

@en

P2093

David F Jarrard

http://www.w3.org/2001/XMLSchema#string

Michael L Blute

http://www.w3.org/2001/XMLSchema#string

Nathan A Damaschke

http://www.w3.org/2001/XMLSchema#string

P2860

The polycomb group protein EZH2 is involved in progression of prostate cancer

Quantitative assessment of DNA methylation: Potential applications for disease diagnosis, classification, and prognosis in clinical settings.

Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending.

Promoter Methylation in Prostate Cancer and its Application for the Early Detection of Prostate Cancer Using Serum and Urine Samples.

Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Epigenetic susceptibility factors for prostate cancer with aging.

Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate.

GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer.

Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene.

P304

83-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MOU.0000000000000132

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25405932

http://www.w3.org/2001/XMLSchema#string

P921

P932

5526656

http://www.w3.org/2001/XMLSchema#string